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In this issue of Structure, Bunney and colleagues use a combination of NMR, SAXS, crystallography, ITC, and
biochemical methods to elucidate, in molecular detail, the sequence of events causing receptor-mediated
activation of phospholipase C-g1 by protein tyrosine phosphorylation.Inositol phospholipid-specific phospholi-
pases C (PLCs) catalyze the hydrolysis
of phosphatidylinositol 4,5-bisphosphate
(PtdInsP2) to produce inositol 1,4,5-
trisphosphate (InsP3) and diacylglycerol
(DAG). The enzymes thus produce three
immediate intracellular messages: in-
creased InsP3 (and, consequently, a rise
in intracellular Ca2+), increased DAG
(causing enhanced activity of protein
kinases C), and decreased PtdInsP2. The
local concentration of the latter in the
plasma membrane and, possibly, in other
cellular membranes regulates the activi-
ties and/or subcellular distribution of
many regulatory or structural proteins,
including enzymes, ion channels and
transporters, transcription factors, scaf-
folding proteins, and cytoskeletal pro-
teins. The thirteen mammalian PLC
isozymes are divided into six subfamilies,
designated b, g, d, ε, z, and h (Kadamur
and Ross, 2012). The four members of
the PLCb subfamily are activated by
heterotrimeric G protein Gaq and Gbg
subunits as well as, in the case of
PLCb2, by the Rho GTPases Rac and
Cdc42. The two members of the PLCg
family, g1 and g2, are activated by re-
ceptor and nonreceptor protein-tyrosine
kinases. PLCg2, but not PLCg1, is also
activated by Rac. In addition, alternative
mechanisms exist to regulate the activity
of the two PLCg isoforms. The regulation
of the other PLC isoforms (d-h) is less
clear, although they too may be activated
by increased intracellular Ca2+ (d-h), het-
erotrimeric G protein subunits (ε, h), and
small GTP-binding proteins (d, ε). Intrigu-
ingly, some of the cellular functions of
PLCg isozymes appear to be independent
of their catalytic activity (e.g., Swiercz
et al., 2009).
The molecular mechanisms of activa-
tion of the PLC isozymes in intact cells,
in particular by regulatory proteins andby tyrosine phosphorylation, have long
been obscure and have only recently
been elucidated by structural studies.
Thus, analysis of the three-dimensional
structure of a truncated form of PLCb2
revealed that the active site of the enzyme
is occluded by a small segment of the re-
gion separating the two halves (X and Y) of
the catalytic triose phosphate isomerase
barrel (Hicks et al., 2008). Deletion of this
segment constitutively activates PLCb2
without ablating its capacity to be further
stimulated by Gaq, Gbg, or Rac. Similar
regulation occurs in other PLC members
(d, ε). This has led to the proposal of a
general mechanism of interfacial PLC
isozyme activation. According to this
model, the various protein activators
would anchor and orient the PLCs at
substrate membranes to release autoinhi-
bition by the XY linker and to promote
access of PtdInsP2 to the lipase active
site. However, several lines of evidence
suggest that other mechanisms of PLC
autoinhibition and activation exist, even
for PLCb (Lyon et al., 2011), but also for
PLCz (Nomikos et al., 2012) and the
PLCg isozymes, which do not contain
negative charges in their XY linkers at
the high density critical in other PLCs for
interfacial activation and are not activated
by deletion of a segment corresponding
to the autoinhibitory XY linker segment
of PLCb2 (unpublished data).
The sequence linking X and Y in PLCg
isozymes is unique and encodes a
modular tandem comprising, in this order,
the N-terminal half of a split PH domain
(nsPH), an N-terminal SH2 domain
(nSH2), a C-terminal SH2 domain (cSH2),
an SH3 domain, and the C-terminal half
of the spPH domain (csPH). The whole
tandem is also referred to as specific array
(SA). Previous results on the activation of
PLCg1 by tyrosine phosphorylation have
shown that nSH2 is important for recogni-Structure 20, December 5, 2012 ªtion of phosphorylated tyrosine re-
sidues on activated cell surface tyrosine
kinase receptors, whereas cSH2 inter-
acts, in an intramolecular fashion, with
the major phosphorylated tyrosine of
PLCg1, Y783, located immediately down-
stream of cSH2 (Poulin et al., 2005;
Gresset et al., 2010).
The work by Bunney et al. (2012) in this
issue ofStructure reports the structures of
thewhole PLCg1 SA (aswell as single, iso-
lated domains and combinations thereof),
as determined by 2D 15N,1H-HQSC NMR
spectroscopy and the structure of the
tandem nSH2-cSH2 pair solved by X-ray
crystallography. Cross peaks detected in
isolated cSH2 were not observed (in
contrast to those corresponding to the
other SA constituents) unless SH2 domain
ligand peptides were present, suggesting
that the latter may destabilize transient
interactions between cSH2 and the rest
of SA. Such interactions may occur
between the cSH2 and both nsPH and
SH3. The tandem nSH2-cSH2 pair
displays relatively low intramolecular flex-
ibility with respect to each other. MONSA
and XPLOR-NIH analysis of SAXS data
revealed that the spPH and cSH2
domains form the central lobe of the SA
molecular volume, which is sandwiched
between the nSH2 and SH3. The crystal
structure of nSH2-cSH2 (including the
cSH2-SH3 linker containing phosphory-
lated Y783) showed that the side chains
of the latter and three adjacent residues
make multiple interactions with the con-
served pY binding site of cSH2 without
changing the overall structure of the
domain. Comparison of the binding of
the Y783-phosphorylated and the non-
phosphorylated nSH2-cSH2 domain to
activated, Y766-phosphorylated FGFR-1
by ITC revealed that wild-type nSH2-
cSH2 interacted with the receptor with
high (KD 5 nM) and low affinities2012 Elsevier Ltd All rights reserved 1989
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pY783 interacted with the receptor via
only a single binding site with an interme-
diate affinity (KD 44 nM). Collectively,
these results and other evidence pre-
sented in the paper suggest that phos-
phorylation of Y783 of PLCg1 weakens
the interaction of the enzyme with the
activated receptor. To investigate the
connection between Y783 phosphoryla-
tion and increased PLCg1 activity, the
interaction in trans of 15N-labeled nSH2,
cSH2, and spPH with the PLCg1 core
lacking SA was examined by NMR titra-
tion. Most intriguingly, only cSH2 showed
changes in its NMR spectrum, and these
changes were completely reversed in the
presence of the phosphorylated cSH2-
SH3 linker peptide containing pY783.
These findings and other evidence imply
that cSH2 is, in fact, the only SA constit-
uent that interacts with the PLCg1 core
containing its catalytic domain and that
this interaction can be released following
Y783 phosphorylation and intramolecular
association with the cSH2 domain.
Finally, the authors used biochemical ex-
periments to demonstrate that the associ-
ation of wild-type, full-length PLCg1 with
activated FGFR-1 is greatly decreased
following PLCg1 phosphorylation and
that phosphorylated, isolated PLCg1
retains high activity without the require-
ment of sustained binding to activated
FGFR-1.
The findings reported in this work have
several important implications. First, they
strongly suggest amodel of PLCg1 activa-
tion by tyrosine kinase growth factor
receptors, consisting of an initial and
transient strong interaction between the
receptor and PLCg1, mediated by nSH2,
followed by phosphorylation of PLCg1
cSH2-mediated release of catalytically
active PLCg1 from the receptor, and,
possibly, processive phosphorylation of
many PLCg1 molecules by a single acti-1990 Structure 20, December 5, 2012 ª2012vated receptor. Depending on the relative
lifetimes of the activated states of the
individual proteins, this could lead to
signal amplification at a very early step
of signal transduction, similar to that
observed, in many cases, for the activa-
tion of heterotrimeric G proteins by their
receptors (e.g., Arshavsky et al., 2002).
Second, the structural alterations ob-
served in the PLCg1 SA during receptor-
mediated activation may help to under-
stand the molecular mechanisms
involved in activation of PLCg2 by chemi-
cally induced or spontaneously occurring
mutations in the mouse Plcg2 and the
human PLCG2 genes, respectively, and
giving rise to specific autoimmune
diseases in mice and humans, such as
cold-induced urticaria and immune dysre-
gulation (see Zhou et al., 2012 for refer-
ences). Intriguingly, several of these
mutations map to cSH2 or the interface
between csPH and cSH2, as determined
in the study reported in this issue.
It seems clear that this work leaves
certain aspects open and raises new
questions. For example, it is unclear to
what extent the findings reported here
for PLCg1 can be extrapolated to PLCg2,
which plays important, specific roles in,
e.g., B cells, monocytes/macrophages,
mast cells, and platelets. Analysis in intact
B cells suggests that phosphorylation of
more than one site may be required for
full enzyme activation (e.g., Watanabe
et al., 2001). Second, the functional roles
of the other PLCg1 SA constituents,
such as sPH and SH3, and phosphoryla-
tion(s) of PLCg1 at sites potentially func-
tionally relevant in other cellular contexts
and for other types of stimuli, such as
Y775 and Y1253, remain to be integrated
into the model suggested here. Finally,
many of the results presented in this
paper were (and had to be) done in trans-
fected cells or cell-free preparations. It is
clear that experiments in native cells willElsevier Ltd All rights reservedbe required to determine the validity of
the concepts derived in this very elegant
study for the behavior of PLCg1 in natural
plasma membranes and more complex
cellular environments.ACKNOWLEDGMENTS
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